Abciximab readministration: Results of the ReoPro Readministration Registry

Circulation

Volumn 104, Issue 8, 2001, Pages 870-875

  Tcheng, James E ^a,j   Kereiakes, Dean J ^b   Lincoff, A Michael ^c   George, Barry S ^d   Kleiman, Neal S ^e   Sane, David C ^f   Cines, Douglas B ^g   Jordan, Robert E ^h   Mascelli, Mary Ann ^h   Langrall, Mary Ann ^h   Damaraju, Lakshmi ^h   Schantz, Allen ^h   Effron, Mark B ⁱ   Braden, Gregory A ^f  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b The Carl & Edyth Lindner Center for Research & Education   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Midwest Cardiol Research Foundation   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h CENTOCOR INC   (United States)

ⁱ ELI LILLY AND COMPANY   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Angioplasty; Pharmacodynamics; Platelet aggregation inhibitors; Thrombocytopenia

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST;

ARTICLE; BLEEDING; CORONARY ARTERY DILATATION; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; HYPERSENSITIVITY REACTION; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; TREATMENT INDICATION;

EID: 0035928845     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc3301.094533     Document Type: Article

References (23)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
2. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
3. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina
4. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade
5. Glycoprotein IIb/IIIa integrin blockade
6. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
7. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study
8. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI)-14 trial
9. A new murine monoclonal antibody reports an activationdependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex
10. γβ3
11. Safe use of platelet GP IIb/IIIa inhibitors
12. Abciximab readministration: A single-operator community-hospital experience
13. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia
14. Heparin-associated thrombocytopenia
15. 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia
16. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions
17. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy
18. Abciximab-associated profound thrombocytopenia: Therapy with immunoglobulin and platelet transfusion
19. Understanding thrombocytopenia and antigenicity with giycoprotein IIb-IIIa inhibitors
20. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
21. Heparin-induced thrombocytopenia
22. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT